# [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors

> **NCT05490264** · EARLY_PHASE1 · UNKNOWN · sponsor: **SmartNuclide Biopharma** · enrollment: 20 (estimated)

## Conditions studied

- Solid Tumor
- Positron-Emission Tomography(PET)

## Interventions

- **BIOLOGICAL:** [68Ga]Ga-NOTA-SNA002

## Key facts

- **NCT ID:** NCT05490264
- **Lead sponsor:** SmartNuclide Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-18
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05490264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05490264, "[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05490264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*